Key Highlights
- Shares of Travere Therapeutics (TVTX) climbed 44% following regulatory clearance for FILSPARI in treating FSGS
- FILSPARI represents the inaugural FDA-sanctioned treatment option for focal segmental glomerulosclerosis
- The regulatory clearance encompasses both adult patients and pediatric cases starting at age 8 without nephrotic syndrome
- The potential patient population in the United States exceeds 30,000 individuals
- Guggenheim analysts elevated their TVTX price target from $49 to $54 while reiterating their Buy recommendation
Travere Therapeutics (TVTX) witnessed a substantial 44% surge in share value Tuesday following regulatory authorization from the FDA for FILSPARI (sparsentan) as a treatment for focal segmental glomerulosclerosis — a condition affecting the kidneys that previously lacked any sanctioned therapeutic options.
Travere Therapeutics, Inc., TVTX
The regulatory approval encompasses adult patients along with pediatric cases beginning at age 8 diagnosed with FSGS who are not experiencing nephrotic syndrome. FILSPARI now stands as the pioneering FDA-sanctioned medication for this particular condition.
This regulatory victory also represents the second rare kidney disorder indication for FILSPARI, which previously received authorization for treating IgA nephropathy.
According to Travere’s estimates, the eligible patient population within the United States surpasses 30,000 individuals with FSGS who satisfy the specified criteria — specifically those not exhibiting the three simultaneous indicators of nephrotic syndrome.
Clinical Trial Results
The regulatory decision drew support from the Phase 3 DUPLEX Study, characterized as the most extensive interventional clinical investigation ever conducted for FSGS.
Participants receiving FILSPARI experienced a 46% decrease in proteinuria levels measured from initial baseline through Week 108. In contrast, those administered the comparison medication, maximum-dose irbesartan, demonstrated a 30% reduction.
Within the specific patient subset not presenting nephrotic syndrome, FILSPARI achieved a 48% proteinuria reduction compared to 27% observed with irbesartan.
Patients treated with FILSPARI in this particular cohort additionally demonstrated favorable outcomes in eGFR measurements, showing a treatment differential of 1.1 mL/min/1.73 m² at the 108-week mark.
The medication exhibited a safety profile that aligned closely with irbesartan across both adult and younger patient populations — a favorable outcome that should support commercial acceptance.
Wall Street Response
Guggenheim’s Vamil Divan increased his valuation target for TVTX from $49 to $54 while maintaining his Buy recommendation in response to the announcement.
Divan indicated the final approved labeling exceeded market expectations, highlighting that the authorized patient population proved broader than Wall Street analysts had anticipated.
More specifically, the labeling encompasses both primary and secondary FSGS variants — extending beyond merely the primary and genetic subtypes that analysts and company leadership had been incorporating into their financial projections.
This expanded coverage creates a substantially larger revenue opportunity than many investors had factored into their valuations.
TipRanks documents an additional analyst Buy recommendation with a $47 valuation target for the equity, while rating the technical sentiment indicator as a Buy.
TVTX’s present market capitalization stands at roughly $2.67 billion following Tuesday’s share price movement.
The FDA authorization was disclosed April 13, 2026, with the market response materializing throughout Tuesday’s trading hours.
